Albireo Pharma, Inc. (NASDAQ:ALBO) last week reported its latest yearly results, which makes it a good time for...
ALBO earnings call for the period ending March 31, 2020.
On track to report topline data mid-2020 BOSTON, March 10, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing.
“Despite its peaceful reputation, Canada is not acting as a benevolent player on the international stage,” warns open letter from activists, artists, and academics. As Canada vies for a temporary seat on the United Nations Security Council an open letter publ…
Read the The Great Sardine Taste-off best canned sardines Next 7 discussion from the Chowhound General Discussion, Canned Fish food community. Join the discussion today.
BOSTON, May 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that.
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced a proposed underwritten public offering of its common stock. In connection with the offering, Albireo intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in the offering. All of the shares in the offering will be sold by Albireo.
One thing we could say about the analysts on Albireo Pharma, Inc. (NASDAQ:ALBO) - they aren't optimistic, having just...
Shares of Albireo Pharma (NASDAQ:ALBO) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share decreased 60.43% year over year to ($2.23), which may not compared to the estimate of ($1.36).Revenue of $1,549,000 higher by 171.75% from the same period last year, which beat the estimate of $1,030,000.Guidance Albireo Pharma hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Conference Call Details Date: May 07, 2020View more earnings on ALBOWebcast URL: http://public.viavid.com/player/index.php?id=138368Recent Stock Performance Company's 52-week high was at $38.6952-week low: $11.26Price action over last quarter: Up 3.09%Company Profile Albireo Pharma Inc is a development-stage pharmaceutical company. It engages in the research and development of drug reformulation technology. The company product portfolio includes Pediatric Liver, Adult Liver, and Gastrointestinal.See more from Benzinga * Recap: International Seaways Q1 Earnings * Recap: Oaktree Specialty Lending Q2 Earnings * Himax Technologies: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...
BOSTON, Feb. 24, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the completion of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. In addition, the underwriters have exercised in full an option to purchase an additional 285,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by Albireo, with gross proceeds to Albireo of approximately $46.0 million and net proceeds of approximately $42.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.
If you're interested in Albireo Pharma, Inc. (NASDAQ:ALBO), then you might want to consider its beta (a measure of...
Biotech stocks came under significant weakness along with the broader market in the week ended Feb. 28. Despite fears the COVID-19 epidemic will likely drag global growth, the viral outbreak proved advantageous for ...
BOSTON, April 07, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. But if...
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,905,000 shares of its common stock at a price to the public of $21.00 per share. Albireo’s gross proceeds from this offering are expected to be approximately $40 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Albireo has granted the underwriters a 30-day option to purchase up to an additional 285,750 shares of common stock on the same terms and conditions.
[New Entry by Vincent C. Müller on April 30, 2020.] Artificial intelligence (AI) and robotics are digital technologies that will have significant impact on the development of humanity in the near future. They have raised fundamental questions about what we s…
Good morning, early birds. Anthony Albanese has a high-speed vision for the economy post-COVID-19, and Chinese authorities are facing a potential new wave of coronavirus cases. It's the news you need to know, with Chris Woods. The post Albo’s need for high sp…
1 out of 23 CEF sectors positive on price and 8 out of 23 sectors positive on NAV last week. A little bit of alpha available from MNE and SRF/SRV mergers. GER/G
There's two ways to look at this market. Either you look at the financial and energy stocks and run for the hills, or you look at technology stocks and look for opportunities.I prefer the latter. And would it surprise you to see that the best-performing techn…
For the first time, the Supreme Court has agreed to review the Computer Fraud and Abuse Act (CFAA). The Court’s initial review of the CFAA comes in the wake of a federal circuit split as to whether the statute can only be deployed against hackers and unauthor…
— Phase 3 odevixibat PFIC trial fully enrolled — — Initiating pivotal trials in biliary atresia first half of 2020 and Alagille syndrome by year end — — Management to.
It's been a good week for Albireo Pharma, Inc. (NASDAQ:ALBO) shareholders, because the company has just released its...
For the first time, the Supreme Court has agreed to review the Computer Fraud and Abuse Act (CFAA). The Court’s initial review of the CFAA comes in the wake of a federal circuit split as to whether the statute can only be deployed against hackers and unauthor…
"You'll do anything I ask?" Quiver has debuted an official trailer for an indie comedy titled Mope, which first premiered at last year's Sundance Film Festival. It also played at the Cinepocalypse, Bucheon Fantastic Film Festival, and Fantasy Filmfest in Germ…
WARNING - GRAPHIC CONTENT: The brutal attack in Bridgewater, Somerset, starts with one of the group jumping over the helpless victim as he lays on the floor dazed and confused.
"A new bull market!" says one. "The crash has only begun!" says another. These are your headlines on Seeking Alpha, which only goes to prove that nobody knows what lies ahead.And after the previous week in which the markets went nowhere, we just had another w…
Given the close relationship between cytokinins (CKs), photosynthesis and nitrogen metabolism, this study assessed the effect of arsenic (As) contamination on these metabolic components in the As-hyperaccumulators Pteris cretica L. var. Albo-lineata (Pc-A) an…
Despite its peaceful reputation, Canada is not acting as a benevolent player on the international stage. Rather, Canada ranks among the twelve largest arms exporters and its weapons have fueled conflicts across the globe, including the devastating war in Yeme…
CEBU CITY, Philippines — Policemen from the Pardo Police Station are now conducting a hot pursuit operation on the man who shot dead his neighbor who ran amok in his neighborhood in Sitio Living Water, Barangay Basak Pardo here on Monday evening, May 4, 2020.…
BOSTON, Feb. 26, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
BOSTON, April 30, 2020 -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced.
Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced its support for Rare Disease Day 2020 and reaffirms its commitment to patients and families living with biliary atresia (BA), Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC) and other rare cholestatic diseases. Rare Disease Day (www.rarediseaseday.org) was established by EURORDIS in 2008 and takes place on the last day of February each year to raise global awareness of the risk and impact of rare diseases.
Jon Queally, staff writer "Despite its peaceful reputation, Canada is not acting as a benevolent player on the international stage," warns open letter from activists, artists, and academics.
It’s Saturday, May 9, 2020, and National Foodies Day. Remember the immortal words of Dr. Johnson: ” He who does not mind his belly, will hardly mind anything else.” It’s also Brunch for Lunch Day (remember, though, that Anthony Bourdain said to never go out f…
— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020 —— First sites initiated for second pivotal trial in biliary atresia —— Management to host.
ALBO earnings call for the period ending March 31, 2020.